Related Experiment Video
Updated: Feb 26, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Enhancing user experience with an automated insulin delivery system by upgrading to a next generation sensor
Pilar Isabel Beato-Víbora1, Estela Gil-Poch2, Francisco Javier Arroyo-Díez2
1Endocrinology and Nutrition Department, Badajoz University Hospital, Extremadura University, Badajoz, Spain.
None:
BackgroundThe evaluation of user satisfaction with an automated insulin delivery (AID) system is crucial. The aim was to assess the change in user satisfaction after upgrading from a previous to a next generation sensor integrated in the same AID system.MethodsA prospective intervention study was conducted. Type 1 diabetes subjects simultaneously upgraded from Guardian-Sensor®4 to Simplera-SyncTM, integrated in the MiniMedTM-780G system. User satisfaction was evaluated at baseline and after 3 months of use of Simplera-SyncTM by the Glucose Monitoring Experience Questionnaire (GME-Q), a validated questionnaire designed to evaluate the experience with a glucose monitoring system. Glucose control and use of the system were also compared.ResultsNinety-one subjects were included (age: 38 ± 15 years-old, 59% female). GME-Q global score increased from 3.84 ± 0.49 to 4.40 ± 0.46. All subscales, effectiveness, convenience, and intrusiveness also improved. Sensor use increased from 93% [91, 95] to 98% [96, 99] and time in automode from 94% [92, 97] to 100% [97, 100], with 50% of the subjects achieving 100% of time in automode. A reduction in time in moderate hypoglycaemia and the number of hypoglycaemia episodes was observed.ConclusionUpgrading to a new sensor, as part of an AID system, can improve user satisfaction and allow for increased sensor use and time in automation.
Related Concept Videos
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Modified-Release Drug Delivery Systems: Rate-Programmed I
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Modified-Release Drug Delivery Systems: Stimuli-Activated

